BioMarin International, a global biotechnology company that develops and commercialises innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, announced that it is investing in a new Drug Product Filling Project at its facility in Shanbally, Cork (Ireland).
This project will allow the company to maximize the flexibility of the site with the expansion of the operational manufacturing capacity to meet the rise in the global demand for its therapies to treat rare genetic diseases that mostly affect children.
The Drug Product Filling Project investment estimated at approximately €40 million, which is projected to create an additional 51 roles across all disciplines, will augment the site’s Drug Substance Manufacturing and Secondary Packaging and Labelling capability. A planning application will be submitted in the coming weeks and it is anticipated that an additional 100 personnel will be on site during the construction, commissioning and qualification phases.
Headquartered in San Rafael, California (USA), BioMarin focuses on developing first-in-class and best-in-class therapeutics that have the potential to improve clinical outcomes of patients with rare genetic diseases. The company currently has seven approved products that are the only drugs available on the market today for the diseases they treat.